Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis said. Kisqali was approved as a treatment for early breast cancer by the U.S. Food and Drug Administration in September, and it has been approved as a treatment for metastatic breast ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Breast cancer is the most commonly diagnosed cancer ... therapy," said Patrick Horber M.D., President, International, Novartis. "Together with the recent FDA approval and late-breaking NATALEE ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...

Basel, October 18, 2024 – Novartis announced today that the Committee ... growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC), at high risk of disease recurrence, including ...

significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast cancer 2 People with stage II or III HR+/HER2- EBC face ...

received a score of four out of five for post-menopausal patients with HR+/HER2- advanced breast cancer treated in the first line29. Kisqali was developed by Novartis under a research ...

Press release. FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer. September 17, 2024. Accessed October 15, 2024. /news/media-releases/fda ...